Key Points
- Director Louis Lange sold 28,186 shares on March 6 at an average price of $29.41 for about $828,950, a disclosure that adds to recent concentrated insider selling at the company.
- Quarterly results were weak, with an EPS miss of ($0.63) versus ($0.40) expected, only $0.03M in revenue and deeply negative margins, leaving the company loss-making and sensitive to execution risk.
- Counterbalancing the weak fundamentals, several analysts have raised ratings/targets and the consensus is a "Moderate Buy" with an average target near $47, while large institutions have been increasing stakes, signaling investor optimism.
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) Director Louis Lange sold 28,186 shares of the company's stock in a transaction on Friday, March 6th. The stock was sold at an average price of $29.41, for a total transaction of $828,950.26. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
NewAmsterdam Pharma Stock Performance
Shares of NASDAQ NAMS opened at $31.27 on Wednesday. The company has a market cap of $3.60 billion, a P/E ratio of -18.08 and a beta of 0.04. NewAmsterdam Pharma Company N.V. has a 52-week low of $14.06 and a 52-week high of $42.00. The firm's fifty day moving average is $33.41 and its two-hundred day moving average is $33.36.
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings data on Wednesday, February 18th. The company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. The firm had revenue of $0.03 million for the quarter, compared to analysts' expectations of $0.92 million. As a group, analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.
Key NewAmsterdam Pharma News
Here are the key news stories impacting NewAmsterdam Pharma this week:
- Positive Sentiment: Several sell‑side firms have raised ratings and targets (Needham raised its target to $48, HC Wainwright upgraded to strong‑buy, RBC lifted its target to $47) and the consensus remains a "Moderate Buy" with an average target near $47, supporting upside expectations. MarketBeat analyst note
- Positive Sentiment: Large institutional positions and recent accumulation (Capital World Investors, Jennison, Duquesne and others increased stakes) signal continuing institutional confidence and provide potential buying support under the stock. MarketBeat institutional holdings
- Neutral Sentiment: Recent profile/coverage updates (e.g., Barron's stock page) provide visibility but do not contain new material clinical or financial news likely to immediately change fundamentals. Barron's stock page
- Negative Sentiment: Large, repeated insider sales by CFO/insider Johannes Jacob Piete Kastelein (multiple trades on March 5–9–6 totaling several hundred thousand shares and reducing his stake by roughly ~57–60%) are material — such concentrated selling can pressure the stock and raise investor concern about insider liquidity needs or sentiment. InsiderTrades: Kastelein sales SEC filing
- Negative Sentiment: Director Louis G. Lange sold 28,186 shares (March 6), another disclosed insider sale that adds to the net insider selling narrative. SEC filing
- Negative Sentiment: Recent quarterly results (Feb. 18) showed an EPS miss and very limited revenue, with negative margins — underlying fundamentals remain loss‑making, which keeps the stock sensitive to sentiment and execution risk. MarketBeat earnings summary
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on the stock. Leerink Partners restated an "outperform" rating and issued a $55.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, January 6th. Royal Bank Of Canada lifted their price objective on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 21st. Needham & Company LLC boosted their target price on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a "buy" rating in a report on Wednesday, February 18th. The Goldman Sachs Group increased their price target on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a "neutral" rating in a report on Tuesday, December 2nd. Finally, Stifel Nicolaus lifted their price target on NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a "buy" rating in a research report on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $47.10.
Read Our Latest Stock Report on NewAmsterdam Pharma
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the business. Capital World Investors grew its stake in shares of NewAmsterdam Pharma by 17.1% during the third quarter. Capital World Investors now owns 9,822,711 shares of the company's stock valued at $279,358,000 after buying an additional 1,434,986 shares during the last quarter. Jennison Associates LLC boosted its holdings in NewAmsterdam Pharma by 42.5% during the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company's stock valued at $119,407,000 after acquiring an additional 1,252,451 shares during the period. Duquesne Family Office LLC grew its position in NewAmsterdam Pharma by 131.2% in the 3rd quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company's stock valued at $54,710,000 after acquiring an additional 1,091,525 shares during the last quarter. Castle Hook Partners LP bought a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth $38,062,000. Finally, Adage Capital Partners GP L.L.C. boosted its stake in shares of NewAmsterdam Pharma by 54.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company's stock valued at $54,566,000 after purchasing an additional 1,062,359 shares during the period. Hedge funds and other institutional investors own 89.89% of the company's stock.
NewAmsterdam Pharma Company Profile
(
Get Free Report)
NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.
The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
